Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

10.3%

17 terminated/withdrawn out of 165 trials

Success Rate

86.8%

+0.2% vs industry average

Late-Stage Pipeline

27%

45 trials in Phase 3/4

Results Transparency

16%

18 of 112 completed trials have results

Key Signals

14 recruiting18 with results10 terminated7 withdrawn

Enrollment Performance

Analytics

N/A
39(41.5%)
Phase 3
29(30.9%)
Phase 4
16(17.0%)
Phase 2
7(7.4%)
Phase 1
3(3.2%)
94Total
N/A(39)
Phase 3(29)
Phase 4(16)
Phase 2(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (165)

Showing 20 of 165 trials
NCT07174648Not Yet Recruiting

Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.

Role: lead

NCT07842107Phase 2Not Yet Recruiting

Phase 2/3 Trial of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in DRC

Role: collaborator

NCT02984579Completed

Line Probe Assay Evaluation Study

Role: collaborator

NCT07789743Phase 3Recruiting

Stop Transmission of Gambiense Human African Trypanosomiasis

Role: lead

NCT07783243Recruiting

Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis

Role: lead

NCT06981442Not ApplicableRecruiting

Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes

Role: lead

NCT07636551Not ApplicableRecruiting

Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants

Role: lead

NCT07688083Not Yet Recruiting

Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC

Role: lead

NCT07681752Not Yet Recruiting

Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA

Role: lead

NCT07499739Phase 4Active Not Recruiting

Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo

Role: lead

NCT06839989Phase 2Active Not Recruiting

An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC

Role: lead

NCT05597280Phase 3Recruiting

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy

Role: lead

NCT06599970Active Not Recruiting

Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility

Role: lead

NCT07487350Recruiting

Recurrent Visceral Leishmaniasis in HIV Co-Infection

Role: lead

NCT05879965Recruiting

Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk

Role: lead

NCT05313139Completed

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

Role: lead

NCT06579885Completed

Ocular Complications of Mpox in the Democratic Republic Congo

Role: lead

NCT06064591Completed

Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX

Role: lead

NCT07463040Phase 3Not Yet Recruiting

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

Role: lead

NCT07455318Phase 3Not Yet Recruiting

Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.

Role: lead